chemotherapy
Researchers reported prospective randomized trial data showing non-inferiority of adjuvant treatment guided by minimal residual disease testing.
The firm has launched a validation trial for its in-development QuantiDNA cell-free DNA chemotherapy response assay in late-stage smoking-related cancers.
Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.
Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy
Patients with luminal breast cancer subtypes may do just as well without anthracycline-based chemo and avoid unnecessary toxicities, a study showed.
Sep 17, 2018
Jan 12, 2017